Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

McAlister FA et al. - This meta-regression analyses of beta-blocker heart failure trials demonstrate that the magnitude of survival benefit seen with beta-blockers is statistically significantly associated with the magnitude of heart rate reduction achieved but not the dosage of beta-blocker administered. However, because no heart failure trials have randomly assigned participants who receive beta-blockers to different target heart rates and the authors did not find an inflection point in this meta-regression for heart rate reduction, the optimal heart rate (and thus target heart rate reduction) is unknown. Thus, 2 questions remain unanswered: Is there any additional benefit to up-titrating beta-blocker dose to trial doses if substantial heart rate reduction has already been achieved with a lower dose? Is there any additional benefit to increasing beta-blocker dose above trial doses if heart rate reduction is minimal?


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address